CN102949409B - Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer - Google Patents
Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer Download PDFInfo
- Publication number
- CN102949409B CN102949409B CN201210443889.1A CN201210443889A CN102949409B CN 102949409 B CN102949409 B CN 102949409B CN 201210443889 A CN201210443889 A CN 201210443889A CN 102949409 B CN102949409 B CN 102949409B
- Authority
- CN
- China
- Prior art keywords
- lachnum
- extracellular polysaccharide
- gastric ulcer
- gastric
- ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of using lachnum exopolysaccharide to prepare a medicine for preventing gastric ulcer. The application comprises the following steps of: using exopolysaccharide powder generated by the lachnum with a culture collection number being CCTCC No:M 2011196 and 0.9% normal saline to prepare 100-400mg/mL aqueous solution, wherein the dosing volume is 10mL/kg; a mouse is subjected to gavage; after two weeks, taking the stomach, observing, determining the ulcer area, calculating the gastric ulcer index, determining the activity of pepsase, the amount of gastric juice and the total acidity of the gastric juice of the mouse, as well as the activity of superoxide dismutase and the content of malondialdehyde in mouse serum. Proved by experiment, the invention has the advantages that the exopolysaccharide generated by the lachnum with the culture collection number being CCTCC No:M 2011196 not only can effectively prevent the gastric ulcer of the mouse, but also has no toxic and side effects, and the preparation method is simple and economic, so that the exopolysaccharide of the lachnum is capable of being applied in being prepared into a tablet or capsule medicine for preventing the gastric ulcer.
Description
Technical field
The invention belongs to the applied technical field of Lachnum extracellular polysaccharide in pharmaceutical field, be specifically related to extracellular polysaccharide that Lachnum produces that culture presevation is numbered CCTCC No:M 2011196 as the application process of preparing preventing gastric ulcer medicine.
Background technology
Gastric ulcer is a kind of common digestive system disease, and because its sickness rate is more and more higher, clinical symptoms is not obvious, and potential hazard is larger, therefore more and more receives people's concern.Mechanism of Gastric Ulcer mechanism is different, as: Pylorus Ligated Gastric Ulcer is the chronic gastric ulcer that gastric acid and pepsin dyssecretosis cause, dehydrated alcohol type gastric ulcer is the acute gastric ulcer causing due to ethanol coup injury gastric mucosa.
Normally used medicine mainly contains alkaline antacid, receptor blocking agent, proton pump inhibitor, gastric mucosa protective agent and antibiotic etc. clinically at present; but above-mentioned existing medicine because of the course for the treatment of longer; and after taking medicine, be prone to sense of discomfort and have toxic and side effects in various degree, making a lot of patients cannot accept long-term treatment.Therefore, excavate natural with exploitation, have no side effect and preventing gastric ulcer medicine that can long-term taking has great importance to safeguarding human health.
Polysaccharide is a class natural polymer, conventionally almost non-toxic.It is the widely distributed saprophytic property of class fungus that Lachnum belongs to (Lachnum Retz.), can produce various bioactivators, as polysaccharide, polyphenol, pigment etc. under liquid culture condition.China's " drug research " (the 20th volume the 1st phase 14-15 page in 2011) discloses the effect research of lycium barbarum polysaccharide to Experimental Gastric Ulcer in Rats, experimental result shows that lycium barbarum polysaccharide has the function of anti-experimental character gastric ulcer, but the lycium barbarum polysaccharide relating in document is plant source polysaccharide, do not mention the preventing gastric ulcer function of microbial source polysaccharide; China Patent No. ZL201010582408.6 discloses a kind of Lachnum polysaccharide in the application of preparing in anti-fatigue medicament.Lachnum and the purposes of extracellular polysaccharide in lowering blood fat and benefiting liver medicine thereof that culture presevation is numbered CCTCC No:M 2011196 are disclosed in Chinese Patent Application No. 201110184104.9 first.But mention using Lachnum extracellular polysaccharide as the report of application aspect of preparing preventing gastric ulcer medicine so far there are no open source literature.
Summary of the invention
The invention provides a kind of extracellular polysaccharide that Lachnum is produced that is numbered CCTCC No:M 2011196 using culture presevation as the application process of preparing preventing gastric ulcer medicine, to meet the needs of people to preventing gastric ulcer medicine.
The extracellular polysaccharide that Lachnum is produced that the present invention is numbered CCTCC No:M 2011196 using culture presevation is as the application process of preparing preventing gastric ulcer medicine, it is characterized in that: the Lachnum that culture presevation is numbered to CCTCC No:M 2011196 is inoculated in 4L fermentation tank, culture medium prescription is: glucose 37-47g/L, yeast extract 10-17g/L, glycine 6-7mg/L, MgSO
47H
2o 0.8-1.1g/L, KH
2pO
40.9-1.1gL, coefficient volume ratio is 0.6-0.8, and inoculum concentration is 13-16% by volume, and cultivation temperature is 23-37 DEG C, and ventilation is 0.9-1.1L/min, and speed of agitator is 170-190r/min, and fermentation time is 9-11 days; By fermentation liquid sucking filtration, concentrated after, the ethanol that the mass fraction that adds its 2-4 times volume is 90%-100% is in 4 DEG C of precipitate with ethanol 18-25h, alcohol is analysed to liquid with the centrifugal 8-10min of 4000-5000r/min, remove supernatant, dehydrated alcohol, washing with acetone 2 ~ 3 times for precipitation, then dissolve with distilled water, adopt Sai Wojiefa (Sevag method) deproteinization, the H that is 30% in concentration expressed in percentage by volume
2o
2after a middle 50-55 DEG C insulation is decoloured and is processed, distilled water room temperature dialysis 20-30 hour ,-48 ~-50 DEG C of lyophilizations, obtain Lachnum extracellular polysaccharide powder;
Above-mentioned Lachnum extracellular polysaccharide powder is configured to the aqueous solution that dosage is 100-400mg/mL with the normal saline that mass percentage concentration is 0.9%, administration volume is 9-11mL/kg, gavage mice 2-3 week, dehydrated alcohol gavage is used in last administration after 1 hour, dosage is that every 200g body weight gives 0.9-1.1mL dehydrated alcohol, after 1 hour, pluck eyeball and get blood, de-mice cervical vertebra is put to death, get stomach, observe and measure ulcer area, calculate ulcer index, measure the pepsin activity of mice, superoxide dismutase in gastric juice amount and total acidity gastric juice and mice serum (SOD) activity and malonaldehyde (MDA) content, experimental result confirmation, above-mentioned Lachnum extracellular polysaccharide can not only effectively prevent mouse gastric ulcer, and has no side effect.
The present invention, using Lachnum extracellular polysaccharide as the application process of preparing preventing gastric ulcer medicine, is characterized in that: can be mixed with following dosage form and use:
A, be processed into tablet: the Lachnum extracellular polysaccharide of getting the 300-600g of above-mentioned preparation, after mixing with pharmaceutic adjuvant diluent 200-250g and fluidizer 30-60g, mix homogeneously and make soft material with 250-600mL ethanol again, by this soft material granulate after the wet grain drying obtaining that sieves, finally add lubricant 3-10g to mix rear tabletting, make 1000, tablet; Described pharmaceutic adjuvant diluent is selected dextrin or dried starch; Described fluidizer adopts Pulvis Talci or micropowder silica gel or microcrystalline Cellulose; Described lubricant adopts magnesium stearate or zinc stearate;
Or B, be processed into capsule: after getting pharmaceutic adjuvant diluent 200-270g, fluidizer 40-70g and wetting agent 3-6g and mixing, after mixing homogeneously with the Lachnum extracellular polysaccharide of 300-600g, be distributed in 1000 1# Capsuleses, make 1000 of capsules; Described pharmaceutic adjuvant diluent is selected dextrin or dried starch; Described fluidizer adopts Pulvis Talci or micropowder silica gel or microcrystalline Cellulose; Described wetting agent adopts sodium lauryl sulphate or dioctyl sulphosuccinate.
The present invention uses extracellular polysaccharide that Lachnum produces that culture presevation is numbered CCTCC No:M 2011196 for raw material is as the application of preparing preventing gastric ulcer medicine, prepared medicine overcome existing alkaline antacid, receptor blocking agent, proton pump inhibitor, gastric mucosa protective agent and antibiotic etc course for the treatment of long and there is the shortcomings such as toxic and side effects in various degree.Confirm through experimentation of the present invention, above-mentioned Lachnum extracellular polysaccharide can not only effectively prevent mouse gastric ulcer, and have no side effect, its preparation method simple economy, therefore can be applied to the medicine of preparing tablet or capsule formulation preventing gastric ulcer by above-mentioned Lachnum extracellular polysaccharide.
Brief description of the drawings
Fig. 1 is the photo comparison of the Mouse Stomach after different disposal, wherein: A is that normal group, the negative matched group of B, C are that polysaccharide low dose group, D are that dosage group in polysaccharide, E are the photo of the Mouse Stomach of polysaccharide high dose group, the positive matched group of F.
Detailed description of the invention
Embodiment 1:
One, the preparation of Lachnum extracellular polysaccharide:
The Lachnum that culture presevation is numbered to CCTCC No:M 2011196 is inoculated in 4L fermentation tank, and culture medium prescription is: glucose 40g/L, yeast extract 12g/L, glycine 6.2mg/L, MgSO
47H
2o 1g/L, KH
2pO
41gL, coefficient is 0.7, inoculum concentration is 15%(volume ratio), cultivation temperature is 35 DEG C, and ventilation is 1.0L/min, and speed of agitator is 180r/min, and fermentation time is 10 days; By fermentation liquid sucking filtration, concentrated after, the ethanol that the mass fraction that adds its 3 times of volumes is 95%, in 4 DEG C of precipitate with ethanol 24h, is analysed liquid with the centrifugal 10min of 5000r/min by alcohol, remove supernatant, dehydrated alcohol, washing with acetone 2 ~ 3 times for precipitation, then dissolve with distilled water, Sevag method deproteinization and 30% H
2o
2after insulation (50 DEG C) decolouring is processed, distilled water room temperature dialysis 24h ,-50 DEG C of lyophilizations, obtain culture presevation and are numbered the extracellular polysaccharide that Lachnum produces of CCTCC No:M 2011196.
Two, the preparation of Lachnum extracellular polysaccharide normal saline solution:
The aqueous solution that above-mentioned Lachnum extracellular polysaccharide powder is configured to respectively to 100mg/mL, 200mg/mL and 400mg/mL with 0.9% normal saline, the administration volume of taking is 10mL/kg.
Three, the effect pharmacological evaluation of Lachnum extracellular polysaccharide to mice preventing gastric ulcer:
(1) animal: 60 of kunming mices, male and female half and half, body weight 22 ± 2g, random packet.
(2) test kit: superoxide dismutase (SOD) and malonaldehyde (MDA), for building up the product that Bioengineering Research Institute produces in Nanjing; Positive drug: thiosugar aluminium flake is the product of Yan'an, Shanghai everything pharmaceutcal corporation, Ltd production.
(3) method: mice adapts to be divided at random 6 groups after a week under experimental situation, every group 10, be respectively: dosage group (200mg/kg), polysaccharide high dose group (400mg/kg), positive controls (thiosugar aluminium flake 150mg/kg) in Normal group, negative control group (normal saline of percentage concentration 0.9%), polysaccharide low dose group (100mg/kg), polysaccharide.When every morning 10:00, respectively each group of mice carried out to corresponding gavage processing, give the tested material of different volumes according to Mouse Weight, freely ingest and drink water, successive administration 14 days, mice fasting 24 hours before last administration, during fasting, drinking-water is not limit, dehydrated alcohol gavage is used in last administration after 1 hour, dosage is that every 200g body weight gives 1mL dehydrated alcohol, after 1 hour, pluck eyeball and get blood, de-mice cervical vertebra is put to death.
(4) index of correlation is measured:
The mensuration of mice gastric secretion, acid concentration and pepsin activity:
Mice is cut open the belly and gets stomach, collect gastric juice, then the gastric juice of collection is moved in graduated centrifuge tube, record gastric juice total amount.With the centrifugal 5min of 4000r/min, get supernatant gastric juice 0.1mL, add 1 of phenol red indicator, with 0.001mol/L NaOH titration, transfer in red 2 seconds and not disappearing for terminal until gastric juice is first after yellow, calculating the NaOH amount exhausting is total acidity.Get supernatant gastric juice, measure pepsin activity according to test kit explanation.
The mensuration of gastric ulcer suppression ratio:
Inject from mice pylorus the formalin that 3mL percentage concentration is 4%, stomach is immersed in formalin and fixed after 30min, cut along greater gastric curvature, wipe gently gastric content with dry cotton balls, perusal Mouse Gastric Mucous Membrane, measure gastric mucosa ulcer length and width (ulcer of not enough 1mm is pressed 1mm meter), calculate ulcer area; Consider each group of Mouse Stomach size difference, weigh the inhibitory action of Polysaccharides on Mice gastric ulcer with ulcer index.Wherein:
Ulcer index=gastric ulcer area/gastric surface long-pending × 100%;
Ulcer inhibition rate=(model control group ulcer index-administration group ulcer index)/model control group ulcer index × 100%.
The mensuration of superoxide dismutase in mice serum (SOD) activity and malonaldehyde (MDA) content:
The centrifugal 5min of 8000r/min, separation of serum, in strict accordance with the explanation of test kit, the content of MDA and SOD in mensuration mice serum.
(5) experimental result:
Gavage Lachnum extracellular polysaccharide, after 2 weeks, obtains each processed group Mouse Gastric Mucous Membrane photo as shown in fig. 1.Wherein: A is that normal group, the negative matched group of B, C are that polysaccharide low dose group, D are that dosage group in polysaccharide, E are the photo of the Mouse Stomach of polysaccharide high dose group, the positive matched group of F.
From Fig. 1 photo: it is red that normal group Mouse Gastric Mucous Membrane is breast, and stomach is complete clear; Negative control group Mouse Gastric Mucous Membrane takes on a red color, glandular stomach portion redness, hyperemia, and have the hemorrhage and mucosal erosion of lamellar; Polysaccharide group Mouse Stomach mucosa redness, congested degree obviously alleviate, visible point-like and a small amount of streak hemorrhage; Positive controls Mouse Gastric Mucous Membrane situation and normal group mice are more or less the same.
Table 1 has provided the impact of Lachnum extracellular polysaccharide on each group of mice index of correlation:
The impact of table 1 Lachnum extracellular polysaccharide on each group of mice index of correlation
Note: in table 1,
ap<0.05, compared with model control group;
bp<0.01, compared with model control group;
cp<0.05, compared with positive controls;
dp<0.01, compared with positive controls.
Each group of index parameter in his-and-hers watches 1 compares analysis, can find out the impact of Lachnum extracellular polysaccharide on each processed group mice index of correlation.
Compared with negative control group, each dosage polysaccharide has all significantly reduced the ulcer index of mice, the ulcer inhibition rate of showed different.Than normal group, model control group Mouse Stomach proteinase activity, gastric juice amount and total acidity gastric juice all obviously raise, and gavage Lachnum extracellular polysaccharide is after 2 weeks, and basic, normal, high dosage polysaccharide all makes it significantly reduce, and is certain dose-effect relationship.Show that this polysaccharide can significantly suppress Mouse Stomach proteinase activity and gastric secretion, reduce total acidity gastric juice, thereby reduce the ulcer index of mice, suppress the generation of gastric ulcer.
Compared with negative control group mice, in each dosage polysaccharide group mice serum, SOD activity is significantly increased, MDA content significantly reduces, wherein in high dose polysaccharide group mice serum, SOD activity has improved 40.47%, MDA content has reduced by 49.27%, and both all have utmost point significant difference (p<0.01).Above result shows that Lachnum extracellular polysaccharide can obviously improve SOD activity in mice serum, reduces MDA content, shows its preventing gastric ulcer function.
The most representative index of mouse gastric ulcer disease has been measured in above-mentioned pharmacological experiment analysis, as can be seen from the above results, in the time that dosage is 100-400mg/ (kg bw), the Lachnum product extracellular polysaccharide that culture presevation is numbered CCTCC No:M 2011196 has significant preventing gastric ulcer effect, can significantly suppress the ulcer index of ulcer mice, improve ulcer inhibition rate, reduce pepsin activity, gastric juice amount and total acidity gastric juice, improve SOD activity in serum, reduce MDA content, show obvious preventing gastric ulcer function.
Embodiment 2:
First prepare Lachnum extracellular polysaccharide by following condition and mode:
The Lachnum that culture presevation is numbered to CCTCC No:M 2011196 is inoculated in 4L fermentation tank, and culture medium prescription is: glucose 46gL, yeast extract 14g/L, MgSO
47H
2o 1.1g/L, KH
2pO
41.1gL, coefficient is 0.8, and inoculum concentration is 15%, and cultivation temperature is 25 DEG C, and ventilation is 1.0L/min, and speed of agitator is 190r/min, and fermentation time is 9 days; By fermentation liquid sucking filtration, concentrated after, the ethanol that the mass fraction that adds its 3 times of volumes is 95%, in 4 DEG C of precipitate with ethanol 18h, is analysed liquid with the centrifugal 10min of 5000r/min by alcohol, remove supernatant, dehydrated alcohol, washing with acetone 2 ~ 3 times for precipitation, then dissolve with distilled water, Sevag method deproteinization and 30% H
2o
2after insulation (55 DEG C) decolouring is processed, distilled water room temperature dialysis 28h ,-48 DEG C of lyophilizations, obtain the Lachnum that culture presevation is numbered CCTCC No:M 2011196 and produce extracellular polysaccharide.
Then the aqueous solution that above-mentioned Lachnum extracellular polysaccharide powder is configured to 100mg/mL, 200mg/mL, 400mg/mL with 0.9% normal saline, administration volume is 10mL/kg.
The Lachnum extracellular polysaccharide of above-mentioned each dosage is carried out to the effect pharmacological evaluation of mice preventing gastric ulcer, the mode step adopting and other conditions are all in the same manner as in Example 1, also all obtained with embodiment 1 in similar result.
The Lachnum extracellular polysaccharide sample that prepared culture presevation is numbered CCTCC No:M 2011196 in application Chinese Patent Application No. 201110184104.9 that this laboratory is preserved is tested according to mode step and the condition of embodiment 1, also all obtained with embodiment 1 in essentially identical result.
The description of test of above-described embodiment, the extracellular polysaccharide that culture presevation is numbered the Lachnum of CCTCC No:M 2011196 can not only effectively prevent mouse gastric ulcer, and have no side effect, its preparation method simple economy, is applied to therefore culture presevation can be numbered to the extracellular polysaccharide of the Lachnum product of CCTCC No:M 2011196 medicine of preparing tablet or capsule formulation preventing gastric ulcer.
Embodiment 3: the processing of Lachnum extracellular polysaccharide preparation
The Lachnum that the present invention is numbered CCTCC No:M 2011196 using culture presevation produces extracellular polysaccharide as the application of preparing preventing gastric ulcer medicine, and the mode that specifically can be processed as following dosage form is used:
1, tablet processing
The Lachnum extracellular polysaccharide of 300-600g and pharmaceutic adjuvant diluent 200-250g, fluidizer 30-60g are mixed to rear 250-600mL ethanol mixs homogeneously and makes soft material, soft material sieves and obtains wet granular, granulate after dry, finally adds lubricant 3-10g to mix rear tabletting, makes 1000 tablets of tablets.Described pharmaceutic adjuvant diluent is selected dextrin or dried starch; Described fluidizer adopts Pulvis Talci or micropowder silica gel or microcrystalline Cellulose; Described lubricant adopts magnesium stearate or zinc stearate.
The preference of the tablet processing that the present invention recommends is: above-mentioned Lachnum extracellular polysaccharide 500g, the diluent dextrin 240g, the fluidizer Pulvis Talci 50g that got 80 ~ 100 mesh sieves, after mix homogeneously, add 400mL ethanol mix homogeneously and make soft material, soft material sieves and obtains wet granular, granulate after dry, finally add magnesium stearate lubricant 10g to mix rear tabletting, make 1000, the heavy 0.8g of sheet, polyoses content 0.5g/ sheet.
2, capsule processing
After mixing homogeneously with the Lachnum YM-281 extracellular polysaccharide of 300-600g after pharmaceutic adjuvant diluent 200-270g, fluidizer 40-70g, wetting agent 3-6g are mixed, fill 1# Capsules, make 1000 of capsules.Described pharmaceutic adjuvant diluent is selected dextrin or dried starch; Described fluidizer adopts Pulvis Talci or micropowder silica gel or microcrystalline Cellulose; Described wetting agent adopts sodium lauryl sulphate or dioctyl sulphosuccinate.
The capsule processing preference that the present invention recommends is: get diluent dried starch 250g, fluidizer Pulvis Talci 45g, wetting agent sodium lauryl sulphate 5g mix homogeneously fills 1000 of 1# Capsuleses, polyoses content 0.5g/ grain after mixing homogeneously with the above-mentioned Lachnum extracellular polysaccharide of 500g.
The present invention uses extracellular polysaccharide that Lachnum produces that culture presevation is numbered CCTCC No:M 2011196 for raw material is as the application of preparing preventing gastric ulcer medicine; prepared medicine can overcome existing alkaline antacid, receptor blocking agent, proton pump inhibitor, gastric mucosa protective agent and antibiotic etc course for the treatment of long and there is the shortcomings such as toxic and side effects in various degree, and preparation method simple economy.
Claims (3)
1. the Lachnum product extracellular polysaccharide that is numbered CCTCC No:M2011196 using culture presevation is as the application of preparing preventing gastric ulcer medicine, be characterised in that described Lachnum produces extracellular polysaccharide, that the Lachnum that culture presevation is numbered to CCTCCNo:M2011196 is inoculated in 4L fermentation tank, culture medium prescription is: glucose 37-47g/L, yeast extract 10-17g/L, glycine 6-7mg/L, MgSO
47H
2o0.8-1.1g/L, KH
2pO
40.9-1.1g/L, coefficient volume ratio is 0.6-0.8, and inoculum concentration is 13-16% by volume, and cultivation temperature is 23-37 DEG C, and ventilation is 0.9-1.1L/min, and speed of agitator is 170-190r/min, and fermentation time is 9-11 days; By fermentation liquid sucking filtration, concentrated after, the ethanol that the mass fraction that adds its 2-4 times volume is 90%-100% is in 4 DEG C of precipitate with ethanol 18-25h, alcohol is analysed to liquid with the centrifugal 8-10min of 4000-5000r/min, remove supernatant, dehydrated alcohol, washing with acetone 2～3 times for precipitation, then dissolve with distilled water, adopt Sai Wojiefa deproteinization, the H that is 30% in concentration expressed in percentage by volume
2o
2after a middle 50-55 DEG C insulation is decoloured and is processed, distilled water room temperature dialysis 20-30 hour ,-48～-50 DEG C of lyophilizations, the Lachnum extracellular polysaccharide obtaining.
2. the Lachnum product extracellular polysaccharide that is numbered CCTCC No:M2011196 using culture presevation is as claimed in claim 1 as the application of preparing preventing gastric ulcer medicine, be characterised in that and be processed into tablet: the 300-600g Lachnum extracellular polysaccharide of getting above-mentioned preparation, after mixing with pharmaceutic adjuvant diluent 200-250g and fluidizer 30-60g, mix homogeneously and make soft material with 250-600mL ethanol again, by this soft material granulate after the wet grain drying obtaining that sieves, finally add lubricant 3-10g to mix rear tabletting, make 1000, tablet; Described pharmaceutic adjuvant diluent is selected dextrin or dried starch; Described fluidizer adopts Pulvis Talci or micropowder silica gel or microcrystalline Cellulose; Described lubricant adopts magnesium stearate or zinc stearate.
3. the Lachnum product extracellular polysaccharide that is numbered CCTCC No:M2011196 using culture presevation is as claimed in claim 1 as the application of preparing preventing gastric ulcer medicine, be characterised in that and be processed into capsule: after getting pharmaceutic adjuvant diluent 200-270g, fluidizer 40-70g and wetting agent 3-6g and mixing, after mixing homogeneously with the 300-600g Lachnum extracellular polysaccharide of above-mentioned preparation, be distributed in 1000 1# Capsuleses, make 1000 of capsules; Described pharmaceutic adjuvant diluent is selected dextrin or dried starch; Described fluidizer adopts Pulvis Talci or micropowder silica gel or microcrystalline Cellulose; Described wetting agent adopts sodium lauryl sulphate or dioctyl sulphosuccinate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210443889.1A CN102949409B (en) | 2012-11-08 | 2012-11-08 | Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210443889.1A CN102949409B (en) | 2012-11-08 | 2012-11-08 | Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102949409A CN102949409A (en) | 2013-03-06 |
| CN102949409B true CN102949409B (en) | 2014-10-08 |
Family
ID=47759168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210443889.1A Expired - Fee Related CN102949409B (en) | 2012-11-08 | 2012-11-08 | Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102949409B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103319619B (en) * | 2013-06-25 | 2015-09-16 | 合肥工业大学 | Lachnum exocellular polysaccharide phosphorylated derivative and preparing the application in antitumor drug |
| CN106832026A (en) * | 2016-12-09 | 2017-06-13 | 合肥工业大学 | Carboxy methylation Lachnum exocellular polysaccharide and its purposes as hypoglycemic drug |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1453295A (en) * | 2003-05-21 | 2003-11-05 | 吉林省生物研究所 | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition |
| CN1546054A (en) * | 2003-12-15 | 2004-11-17 | 上海中医药大学 | Application of wolfberry polyose in the preparation process of gastric ulcer treating medicine |
| CN102250778A (en) * | 2011-07-01 | 2011-11-23 | 合肥工业大学 | Lachnum sp., extracellular polysaccharide thereof and application of extracellular polysaccharide in lipid-lowering liver-favoring medicaments |
-
2012
- 2012-11-08 CN CN201210443889.1A patent/CN102949409B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1453295A (en) * | 2003-05-21 | 2003-11-05 | 吉林省生物研究所 | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition |
| CN1546054A (en) * | 2003-12-15 | 2004-11-17 | 上海中医药大学 | Application of wolfberry polyose in the preparation process of gastric ulcer treating medicine |
| CN102250778A (en) * | 2011-07-01 | 2011-11-23 | 合肥工业大学 | Lachnum sp., extracellular polysaccharide thereof and application of extracellular polysaccharide in lipid-lowering liver-favoring medicaments |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102949409A (en) | 2013-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103386078B (en) | A kind of Chinese medicine composition is preparing the application in treating colon cancer drug | |
| CN102949409B (en) | Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer | |
| CN103272092A (en) | Huoxiang Zhengqi externally-applied preparation and its preparation method and application | |
| CN101849999A (en) | Chinese medicinal composition for treating pelvic inflammation and preparation method thereof | |
| CN102085248B (en) | Traditional Chinese medicinal composition for treating cervix diseases, method for preparing same and method for detecting same | |
| CN103239586A (en) | Flavored agastache turbidity-dispelling external preparation as well as preparation method and application thereof | |
| CN105535738A (en) | Traditional Chinese medicine preparation for treating chronic cough and preparing method thereof | |
| CN104739932A (en) | Preparation method of mangnolia officinalis perfusion fluid for dairy cow mastitis | |
| CN106983790A (en) | A kind of natural biology degradation element killed and suppress cancer cell and preparation method thereof | |
| CN110200926A (en) | Composite reactive freeze-dried powder and its preparation method and application | |
| CN103652490B (en) | Pig feed for treating blue-eared pig disease and preparation method thereof | |
| CN101417130A (en) | Medicine combination for treating II type diabetes and complicating diseases thereof | |
| CN107753669A (en) | A kind of pharmaceutical composition with anti-trioxypurine effect and preparation method thereof and purposes | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN116268414A (en) | Composition for improving gastrointestinal function and preventing constipation and application thereof | |
| CN101584753A (en) | New medical use of Shenshitong preparation | |
| CN102058615B (en) | Novel pharmaceutical application of Lachnum calyculiforme polysaccharides | |
| CN102058616A (en) | Application of soracan gum used as medicine for preventing and treating astriction | |
| CN101485717A (en) | Oral medication for treating pyogenic skin infection | |
| CN104922235B (en) | A kind of coptis chinensis total alkaloid vaginal gel | |
| CN101607009B (en) | Pharmaceutical composition for treating cold | |
| CN102920968A (en) | Application of traditional Chinese medicine composition to preparation of helicobacter pylori resisting medicine | |
| CN104306676A (en) | Traditional Chinese medicine or health product for treating postnatal constipation | |
| CN107095936A (en) | A kind of Chinese medicine composition for relieving sore-throat of detoxifying and preparation method thereof and purposes | |
| CN106106356A (en) | A kind of feeding piglet method based on intelligent use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141008 Termination date: 20171108 |